KIM
MDGL icon

Kestra Investment Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Kestra Investment Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-460
Closed -$241K – 542
2026
Q1 		$241K Buy
460
+15
+3% +$7.17K ﹤0.01% 404
2025
Q4 		$259K Buy
445
+3
+0.7% +$1.53K 0.01% 384
2025
Q3 		$203K Buy
442
+162
+58% +$60.4K 0.01% 428
2025
Q2 		$84.7K Buy
+280
New +$83.4K ﹤0.01% 464

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kestra Investment Management's MDGL Position: Q2 2026 in Review

Kestra Investment Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 460 shares — an estimated $241K sold.

Kestra Investment Management first reported a position in MDGL in Q2 2025 and held it in 4 quarters. The position peaked at $259K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Kestra Investment Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Kestra Investment Management sold 460 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $241K.
  • Kestra Investment Management first reported a position in Madrigal Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Kestra Investment Management's Madrigal Pharmaceuticals position peaked at $259K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Kestra Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.